Miocamycin: Difference between revisions

{{Short description|Chemical compound}}

{{Drugbox

| verifiedrevid = 444015174

| IUPAC_name = (2''S'',3''S'',4''R'',6''S'')-6-<nowiki/>{[(2''R'',3''S'',4''R'',5''R'',6''S'')-6-<nowiki/>{[(4''S'',5''R'',6''S'',7''R'',9''R'',10''R'',11''E'',13''E'',16''R'')-10-(acetyloxy)-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-4-propoxy-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-2,4-dimethyl-3-propoxyoxan-4-yl acetate

| image = Miocamycin.png

<!--Clinical data-->

| tradename =

| Drugs.com = {{drugs.com|international|miocamycin}}

| pregnancy_AUえーゆー = <!-- A / B1 / B2 / B3 / C / D / X -->

| pregnancy_US = <!-- A / B / C / D / X -->

| pregnancy_category =

| legal_AUえーゆー = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->

| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->

| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->

| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->

| legal_status =

| routes_of_administration =

<!--Pharmacokinetic data-->

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

<!--Identifiers-->

| CAS_number = 55881-07-7

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 3T48CPS7U2

| ATC_prefix = J01

| ATC_suffix = FA11

| PubChem = 6475694

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 16735908

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 1091024

<!--Chemical data-->

| C=45 | H=71 | N=1 | O=17

| melting_point = 220

| solubility = Slightly soluble in water; Soluble in methanol, acetone and chloroform.

'''Miocamycin''' is a [[macrolide]] antibiotic.<ref name="pmid7506653">{{cite journal | vauthors = Holliday SM, Faulds D | title = Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential | journal = Drugs | volume = 46 | issue = 4 | pages = 720–45 | date = October 1993 | pmid = 7506653 | doi = 10.2165/00003495-199346040-00008 | s2cid = 195692285 }}</ref> It has a spectrum activity similar to that of [[Erythromycin]], but shows higher antimicrobial effect against certain bacteria including [[Legionella pneumophila]] (the causative agent of [[Legionnaires' disease|Legionnaires' Disease]]), [[Mycoplasma hominis]], and [[Ureaplasma urealyticum]].<ref name="pmid7506653" /> In-vivo studies have further expounded on Miocamycin's efficacy, reporting that the medication is more effective than in-vitro data suggests.<ref>{{Cite journal |last=Lyseng-Williamson |first=Katherine A |date=June 2006 |title=Miocamycin is an effective option in the treatment of various bacterial infections |url=http://link.springer.com/10.2165/00042310-200622060-00001 |journal=Drugs & Therapy Perspectives |language=en |volume=22 |issue=6 |pages=1–6 |doi=10.2165/00042310-200622060-00001 |s2cid=72178165 |issn=1172-0360}}</ref>

== References ==

{{Reflist}}

[[Category:Propionate esters]]